Literature DB >> 11986333

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

W G McCluggage1.   

Abstract

Uterine carcinosarcomas (malignant mixed Mullerian tumours) are highly aggressive and have traditionally been regarded as a subtype of uterine sarcoma. However, in recent years convincing evidence has suggested that most, but not all, are monoclonal in origin rather than true collision tumours. Data confirm that the carcinomatous element is the "driving force" and that the sarcomatous component is derived from the carcinoma or from a stem cell that undergoes divergent differentiation. Thus, uterine carcinosarcomas are best regarded as metaplastic carcinomas, although the designation carcinosarcoma is likely to remain. Adjuvant treatment for uterine carcinosarcoma should probably be similar to that directed against aggressive high grade endometrial carcinomas rather than being sarcoma based. Importantly, a small proportion of uterine carcinosarcomas are true collision tumours and should be recognised as such because, in some instances, the prognosis may be better than for a similar stage carcinosarcoma.

Entities:  

Mesh:

Year:  2002        PMID: 11986333      PMCID: PMC1769650          DOI: 10.1136/jcp.55.5.321

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  56 in total

1.  Collision of endometrioid carcinoma and stromal sarcoma of the uterus: a report of two cases.

Authors:  K Y Lam; U S Khoo; A Cheung
Journal:  Int J Gynecol Pathol       Date:  1999-01       Impact factor: 2.762

2.  Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases.

Authors:  W. G. McCluggage; M. Abdulkader; J. H. Price; P. Kelehan; S. Hamilton; J. Beattie; A. Al-Nafussi
Journal:  Int J Gynecol Cancer       Date:  2000-07       Impact factor: 3.437

3.  Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases.

Authors:  S.A. Szukala; J.R. Marks; J.L. Burchette; A.A. Elbendary; H.R. Krigman
Journal:  Int J Gynecol Cancer       Date:  1999-03       Impact factor: 3.437

4.  Malignant mixed müllerian tumors of the uterus.

Authors:  E O Williamson; W M Christopherson
Journal:  Cancer       Date:  1972-03       Impact factor: 6.860

5.  The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.

Authors:  A C Ansink; P A Cross; P Scorer; A de Barros Lopes; J M Monaghan
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

6.  Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Müllerian tumor) of the uterus?

Authors:  M.J. Evans; N.E.I. Langlois; H.C. Kitchener; I.D. Miller
Journal:  Int J Gynecol Cancer       Date:  1995-07       Impact factor: 3.437

7.  Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.

Authors:  Y Iwasa; H Haga; I Konishi; Y Kobashi; K Higuchi; E Katsuyama; S Minamiguchi; H Yamabe
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

8.  Establishment and characterization of carcinosarcoma cell line of the human uterus.

Authors:  I Gorai; C Doi; H Minaguchi
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

Review 9.  Primary malignant mixed Müllerian tumor (metaplastic carcinoma) of the female peritoneum. A clinical, pathologic, and immunohistochemical study of three cases and a review of the literature.

Authors:  E Garamvoelgyi; L Guillou; S Gebhard; M Salmeron; R J Seematter; M H Hadji
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

10.  Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases.

Authors:  P A de Brito; S G Silverberg; J M Orenstein
Journal:  Hum Pathol       Date:  1993-02       Impact factor: 3.466

View more
  79 in total

1.  T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Authors:  Roberta Nicoletti; Salvatore Lopez; Stefania Bellone; Emiliano Cocco; Carlton L Schwab; Jonathan D Black; Floriana Centritto; Liancheng Zhu; Elena Bonazzoli; Natalia Buza; Pei Hui; Delia Mezzanzanica; Silvana Canevari; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2014-11-15       Impact factor: 5.150

2.  Malignant mixed Mullerian tumors.

Authors:  J Ruiz Tovar; M E Reguero Callejas; J I Arano Bermejo; L F Capote Armas; F González-Palacios Martínez; L Cabañas Navarro
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

3.  Primary carcinosarcoma of the ear: case report and review of the literature.

Authors:  Susun Bellew; James Q Del Rosso; Narciss Mobini
Journal:  J Clin Aesthet Dermatol       Date:  2009-08

4.  Primary carcinosarcoma of the skin.

Authors:  Tijani El Harroudi; S Ech-Charif; M Amrani; A Jalil
Journal:  J Hand Microsurg       Date:  2010-10-19

5.  [New FIGO staging for uterine sarcomas].

Authors:  L-C Horn; D Schmidt; C Fathke; U Ulrich
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

Review 6.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

7.  Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Authors:  Laura Ardighieri; Luigi Mori; Sara Conzadori; Mattia Bugatti; Marcella Falchetti; Carla Maria Donzelli; Antonella Ravaggi; Franco E Odicino; Fabio Facchetti
Journal:  Virchows Arch       Date:  2016-04-08       Impact factor: 4.064

Review 8.  [Current TNM/FIGO classification for cervical and endometrial cancer as well as malignant mixed müllerian tumors. Facts and background].

Authors:  L-C Horn; K Schierle; D Schmidt; U Ulrich; A Liebmann; C Wittekind
Journal:  Pathologe       Date:  2011-05       Impact factor: 1.011

Review 9.  HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.

Authors:  Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

10.  Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype.

Authors:  Erik J Tokar; Bhalchandra A Diwan; Michael P Waalkes
Journal:  Environ Health Perspect       Date:  2010-01       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.